|
66 |
난소암 |
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
|
2024-06-26 |
24 |
|
65 |
난소암 |
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
|
2024-06-26 |
10 |
|
64 |
자궁체부암 |
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
|
2024-06-26 |
5 |
|
63 |
자궁체부암 |
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
|
2024-06-26 |
3 |
|
62 |
기타암 |
Vulvar Carcinoma: Standard of Care and Perspectives
|
2024-06-26 |
6 |
|
61 |
기타암 |
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
|
2024-06-26 |
2 |
|
60 |
자궁경부암 |
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer
|
2024-06-26 |
8 |
|
59 |
자궁경부암 |
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
|
2024-06-26 |
4 |
|
58 |
기타암 |
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center
|
2024-03-29 |
26 |
|
57 |
기타암 |
Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients
|
2024-03-29 |
11 |
